Cynata Therapeutics (CYYNF) Stock Price, News & Analysis

Company Overview

Cynata Therapeutics Limited is an Australian biotechnology company focused on developing cell therapies for serious and chronic diseases. The company’s technology is based on its Cymerus platform, which is designed to produce mesenchymal stem cells (MSCs) at commercial scale from induced pluripotent stem cells. This approach is intended to support the manufacture of consistent, off-the-shelf cell therapy products.

Cynata’s lead program, CYP-001, has been developed as a potential treatment for steroid-resistant acute graft-versus-host disease, a serious complication that can occur after allogeneic stem cell transplantation. The company has also evaluated its MSC products in other areas, including osteoarthritis and cardiovascular or inflammatory conditions, through clinical and preclinical research programs.

Founded in Australia, Cynata has conducted research and clinical development activities through collaborations and studies involving institutions and partners in Australia and overseas. Its work has included partnerships with academic, healthcare and commercial organizations to advance the Cymerus platform and assess potential applications for regenerative medicine.

Key Stats

• Today's Range: $0.0014 to $0.0014
• 50-Day Range: $0.0014 to $0.0086
• 52-Week Range: $0.00 to $0.22
• Volume: N/A
• Average Volume: 100 shs
• Market Capitalization: $332.43 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/15/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:CYYNF
• CIK: N/A
• Web: www.cynata.com
• Phone: 61 3 9824 5254
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 237,450,000
• Free Float: N/A
• Market Cap: $332.43 thousand
• Optionable: Not Optionable
• Beta: 0.16